Our investment
The Voxel S.A. Radiopharmaceuticals Production Centre was established in December 2011 at the 5th Military Teaching Hospital with Policlinic in Cracow, under the auspices of European Union investment, under the priority axis entitled Investments in innovative undertakings, Measure 4.4 IEOP (Innovative Economy Operational Programme): New investments of high innovative potential for the project entitled: "The implementation of innovative production and service team in the medical services sector." This investment, based on world-class technology, including the opening of one of the most advanced PET-CT-MRI diagnostic imaging centres in the country, represents a milestone in the development of diagnostic imaging and nuclear medicine in Poland. For Polish patients, it means better access to diagnostic tests of the highest quality. With this investment, Cracow became home to the first such PET laboratory in the nation.  The second centre of commercial production of radiopharmaceuticals for PET diagnosis in Poland was opened, an extremely important development as it eliminated the need for imports which significantly limited the availability of tests.

Our achievements
In the autumn of 2012, Voxel was GMP-certified and authorised by the Chief Pharmaceutical Inspector to produce fludeoxyglucose (FDG) - the most important radiopharmaceutical used in PET tests. Since then, Voxel has used this product in its five PET centres in Poland. In July 2013, we obtained a permit from the Office for Registration of Medicinal Products to launch a medicinal product made in Cracow, since when - thanks to the contracts we have subsequently entered into - we have supplied FDG to several important nuclear medicine centres in Poland. We have also opened a wholesale outlet of radiopharmaceuticals, and have the appropriate licences to transport them. Thus, we are fully independent as both a manufacturer and supplier, and can supply our radiopharmaceuticals to every customer in our country.

Our technology